These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 29983309

  • 81. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
    Gavaldá C, Bagán JV.
    Med Oral Patol Oral Cir Bucal; 2016 May 01; 21(3):e260-70. PubMed ID: 26827066
    [Abstract] [Full Text] [Related]

  • 82. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
    Zhou YQ, Son GH, Shi YQ, Yu YJ, Li MY, Zhang Q, Zou DH, Zhang ZY, Yang C, Wang SY.
    Int J Med Sci; 2021 May 01; 18(10):2209-2216. PubMed ID: 33859529
    [Abstract] [Full Text] [Related]

  • 83. Medication-related osteonecrosis of the jaw: Evaluation of a therapeutic strategy in oral surgery.
    Natu M, Meuric V, Roginski P, Gamby R, Lejeune S.
    J Stomatol Oral Maxillofac Surg; 2024 Sep 01; 125(5S1):101877. PubMed ID: 38641175
    [Abstract] [Full Text] [Related]

  • 84. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N, Lazarovici TS, Whitefield S, Weissman T, Wasserzug O, Yahalom R.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan 01; 125(1):27-30. PubMed ID: 29102242
    [Abstract] [Full Text] [Related]

  • 85. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
    Yang G, Williams R, Wang L, Farhadfar N, Chen Y, Loiacono AT, Bian J, Holliday LS, Katz J, Gong Y.
    J Bone Miner Res; 2022 Dec 01; 37(12):2466-2471. PubMed ID: 36151778
    [Abstract] [Full Text] [Related]

  • 86. [Drug-induced osteonecrosis of the jaw - not just bisphosphonates].
    Finkelshteyn A, Yarom N.
    Refuat Hapeh Vehashinayim (1993); 2017 Jan 01; 34(1):32-35, 72. PubMed ID: 30699493
    [Abstract] [Full Text] [Related]

  • 87. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, Yamamoto S, Takenobu T, Tomii K, Kawakita M, Katoh H, Ishikawa T, Yasui H, Hashida T.
    Support Care Cancer; 2021 Aug 01; 29(8):4763-4772. PubMed ID: 33527228
    [Abstract] [Full Text] [Related]

  • 88. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug 01; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 89. Epidemiology and pathogenesis of osteonecrosis of the jaw.
    Reid IR, Cornish J.
    Nat Rev Rheumatol; 2011 Nov 29; 8(2):90-6. PubMed ID: 22124271
    [Abstract] [Full Text] [Related]

  • 90. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y, Kanaki T, Yamamoto A, Tanaka R, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI, Ishibashi M, Nishimura K.
    J Bone Miner Metab; 2021 Mar 29; 39(2):295-301. PubMed ID: 32886176
    [Abstract] [Full Text] [Related]

  • 91. What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?
    Colella A, Yu E, Sambrook P, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2023 Feb 29; 81(2):232-237. PubMed ID: 36442534
    [Abstract] [Full Text] [Related]

  • 92. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
    Dos Santos Ferreira L, Abreu LG, Calderipe CB, Martins MD, Schuch LF, Vasconcelos ACU.
    Osteoporos Int; 2021 Dec 29; 32(12):2449-2459. PubMed ID: 34331067
    [Abstract] [Full Text] [Related]

  • 93. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study.
    Otto S, Ristow O, Pache C, Troeltzsch M, Fliefel R, Ehrenfeld M, Pautke C.
    J Craniomaxillofac Surg; 2016 Aug 29; 44(8):1073-80. PubMed ID: 27263757
    [Abstract] [Full Text] [Related]

  • 94. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
    Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, Tierney A, Wagman RB, McClung M.
    J Clin Endocrinol Metab; 2019 Jun 01; 104(6):2443-2452. PubMed ID: 30759221
    [Abstract] [Full Text] [Related]

  • 95. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Bone Miner Res; 2015 Jan 01; 30(1):3-23. PubMed ID: 25414052
    [Abstract] [Full Text] [Related]

  • 96. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y, Yokoi H, Ikeda T, Kawada M, Saito K.
    Auris Nasus Larynx; 2020 Dec 01; 47(6):996-1002. PubMed ID: 32591168
    [Abstract] [Full Text] [Related]

  • 97. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M, Boyd NM, Smith A.
    Aust Dent J; 2014 Dec 01; 59(4):516-9. PubMed ID: 25131835
    [Abstract] [Full Text] [Related]

  • 98. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
    Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb 01; 127(2):117-135. PubMed ID: 30393090
    [Abstract] [Full Text] [Related]

  • 99. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
    Nisi M, Karapetsa D, Gennai S, Ramaglia L, Graziani F, Gabriele M.
    J Craniomaxillofac Surg; 2018 Jul 01; 46(7):1153-1158. PubMed ID: 29802059
    [Abstract] [Full Text] [Related]

  • 100. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.
    Campisi G, Mauceri R, Bertoldo F, Fusco V, Bedogni A.
    Head Face Med; 2021 Jul 09; 17(1):25. PubMed ID: 34243807
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.